DOSAGE REGIMEN OF THERAPEUTIC AGENT OF ATAXIA IN SPINOCEREBELLAR ATAXIA

• 1. 苏云金芽孢杆菌库尔斯塔克亚种和苏云金芽孢杆菌鲇泽亚种组合制剂 [P] . 中国专利： CN111742937A . 2020-10-09
• 2. 苏云金芽孢杆菌库尔斯塔克亚种和苏云金芽孢杆菌鲇泽亚种组合制剂 [P] . 中国专利： CN107428806A . 2017-12-01
• 3. Administration regimen of therapeutic agents for ataxia in spinocerebellar degeneration [P] . JP6860984B2 . 2021-04-21

  机译： 纺织大肠杆菌变性共济失调的治疗剂施用方案

• 4. ADMINISTRATION REGIMEN FOR THERAPEUTIC AGENTS FOR ATAXIA IN SPINOCEREBELLAR DEGENERATION [P] . 美国专利： US2018147189A1 . 2018-05-31

  机译： 脊髓小梁变性的治疗性阿塔克西汀治疗方案

• 5. DOSING REGIMEN OF THERAPEUTIC AGENT FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION [P] . 欧洲知识产权局专利： EP3315128A4 . 2019-02-20

  机译： 与脊髓小梁变性相关的治疗性轴索失禁的剂量方案

• 1. Emerging Concepts of Pathogenesis and Comprehensive Therapeutic Strategies for Spinocerebellar Ataxia Type 3 [J] . Sagor Kumar Roy, Xiaolei Liu 神经系统科学与医药（英文） . 2021,第001期
• 2. The humanδ2 glutamate receptor gene is not mutated in patients with spinocerebellar ataxia [J] . Jinxiang Huang, Aiyu Lin, Haiyan Dong, 中国神经再生研究（英文版） . 2014,第010期
• 3. Prenatal diagnosis of spinocerebellar ataxia type 3/Machado-Joseph disease in mainland China A case report [J] . Lifang Lei, Kun Xia, Beisha Tang, 中国神经再生研究（英文版） . 2011,第026期
• 4. Polyglutamine length-dependent toxicity from ???±1ACT in Drosophila models of spinocerebellar ataxia type 6 Polyglutamine length-dependent toxicity from ???±1ACT in Drosophila models of spinocerebellar ataxia type 6 Polyglutamine length-dependent toxicity from ???±1ACT in Drosophila models of spinocerebellar ataxia type 6 [J] . Christopher M. Gomez, Wei-Ling Tsou, Sultan H. Qiblawi, Biology Open . 2016,第12期
• 5. Phenotype variability and early onset ataxia symptoms in spinocerebellar ataxia type 7: comparison and correlation with other spinocerebellar ataxias [J] . José Luiz Pedroso, Marcus Vinicius Cristino De Albuquerque, Orlando Graziani Povoas Barsottini, Arquivos de Neuro-Psiquiatria . 2015,第1期
• 6. Frequency of Spinocerebellar Ataxia type 1, 2, 3,6 and 7 and clinical profile of Spinocerebellar Ataxia type 3 in Malaysia [J] . Norlinah Mohamed Ibrahim, Yue Hui Lau, Noorasyikin Ariffin, Cerebellum & Ataxias . 2020,第1期
• 7. Role of EMG Rectification for Corticomuscular and Intermuscular Coherence Estimation of Spinocerebellar Ataxia Type 2 (SCA2) [C] . Y. Ruiz-Gonzalez, L. Velazquez-Perez, R. Rodriguez-Labrada, Iberoamerican congress on pattern recognition . 2019
• 8. Infant Onset Spinocerebellar Ataxia Type 13 Mutation Leads to Developmental and Rapid Degenerative Phenotypes Related to Hyperexcitability in Purkinje Cells [D] . Ulrich, Brittany Nicole. 2017
• 9. Analysis of spinocerebellar ataxia types 1 2 3 and 6 dentatorubral-pallidoluysian atrophy and Friedreichs ataxia genes in spinocerebellar ataxia patients in the UK. [O] . J Leggo, A Dalton, P J Morrison, 1997
• 10. Phenotype variability and early onset ataxia symptoms in spinocerebellar ataxia type 7: comparison and correlation with other spinocerebellar ataxias [O] . Marcus Vinicius Cristino de Albuquerque, José Luiz Pedroso, Pedro Braga Neto, 2015

• 1. Spinocerebellar ataxia type 3 with dopamine-responsive dystonia:A case report [J] . Xiao-Le Zhang ,Xiao-Bo Li ,Fa-Feng Cheng . 世界临床病例杂志 . 2021,第028期
• 2. Spinocerebellar Ataxia with Oculomotor Apraxia and Severe Corneal Astigmatism [J] . Paola Michieletto ,Andrea Martinuzzi ,Stefano Pensiero . 眼科学期刊（英文） . 2013,第2期
• 3. 传统CRRT治疗剂量是治疗危重病合并AKI的合适剂量 [C] . 王莉 . 第四届国际腹膜透析学会亚洲地区会议暨2009全国血液净化论坛 . 2009
• 4. 精确放射治疗剂量计算及方案优化方法研究 [A] . 张鹏程 . 2014